Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC

Article Information

DOI 
http://dx.doi.org/10.1177/155989771215010
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2012 MD Conference Express®

Author Information

  1. Toni Rizzo
  1. Alice T. Shaw, MD, PhD
    1. Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, Massachusetts, USA
View Full Text

Article usage

AbstractFullPDF
Apr 2015500
May 2015100
Jul 2015200
Aug 2015900
Sep 2015400
Oct 2015143
Nov 2015110
Total2353

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Cancer
Oncology Clinical Trials
Respiratory Cancers